Exact Sciences Corp (STU:EXK)
€ 50.94 -14.13 (-21.72%) Market Cap: 9.26 Bil Enterprise Value: 10.85 Bil PE Ratio: 0 PB Ratio: 3.15 GF Score: 77/100

Exact Sciences Corp to Discuss Results of the Second-Generation Cologuard Study Call Transcript

Jan 19, 2022 / 04:00PM GMT
Release Date Price: €67.7 (-1.83%)
Operator

Good day, and thank you for standing by. Welcome to the Cologuard 2.0 ASCO GI Data conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Megan Jones. Please go ahead.

Megan Jones
Exact Sciences Corporation - Associate Manager of IR

Thank you, operator, and thank you for joining us to discuss results of the second-generation Cologuard study presented at ASCO GI this week. On the call today are Kevin Conroy, the company's Chairman and CEO; and Dr. John Kisiel, practicing gastroenterologist at Mayo Clinic and Exact Sciences collaborator; Scott Johnson, our Senior Vice President of Research and Development; and Jeff Elliott, our Chief Financial and Chief Operating Officer, will also be available for questions.

We'll only be taking questions on the results of the study today. Exact Sciences issued a news release yesterday afternoon detailing the study results. This news release and today's presentation are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot